jforman

11 ms·

61.
by jforman 10y ago
Startups need moats to fend off existing market bigwigs, story at 10... (this dynamic dates back to the first startup...MSFT ate up an entire ecosystem of startups for a generation)
62.
by jforman 10y ago
Agreed. When I needed a letter of credit BofA refused to issue one to a new company, despite us having ample cash to cover our commercial lease. We switched to SVB, they issued one quickly, and we've been happy ever since. Their tec
63.
by jforman 10y ago
"Does it make the farmers' market unfree when it declares a rule that vendors may not purchase their wares (but must grow the produce/animals on a farm)?" At my local farmer's market vendors are neither contractors
64.
by jforman 10y ago
You seem to want to kill the messenger here. If Uber's practice was unlawful, it would've been stopped eventually. And why was Uber's practice unlawful? The "free market" of contractors Uber relies on to drive dow
65.
by jforman 10y ago
Yeah well I thought GOOG was a dumb investment since >95% of their revenue came from AdWords and surely MSFT & others would pump billions in and make a real dent. The vast majority of their revenue is still from AdWords despite those
66.
by jforman 10y ago
Travis and the Terrible, Horrible, No Good, Very Bad Quarter for PR
67.
by jforman 10y ago
Mitch Kapor founded Lotus, the EFF, Kapor Capital, and the Kapor Center for Social Impact. I don't know exactly where his wife contributed among those things, but they generally refer to themselves as a unit these days so I do, too. H
68.
by jforman 10y ago
Mitch and Freada have already well accomplished "changing the world." Travis has many years to go yet before he can even be considered to be in the same league. As they say, GIGO. Feel free to take on garbage investors, but don&
69.
by jforman 10y ago
Behaving unethically often benefits people in the short-term, but in the long-term it usually ends up a net negative, especially if the behavior keeps up. Uber's founders apparently don't understand this, and have imparted to you
70.
by jforman 10y ago
Mitch has invested in a company I founded before, and I would have him as an investor again in a heartbeat. Your relationship with your investors and your board is both public and private (or at least, it's supposed to be). Yes, you ar
71.
by jforman 10y ago
They were debarred by CMS, not FDA, since CMS regulates clinical labs (mostly). They can still theoretically sell medical devices that are cleared/approved by FDA.
72.
by jforman 10y ago
Real innovation isn't your company doing something in a new way. It's getting your customers to do something in a new way. Medium has unambiguously, objectively succeeded by that metric. They are by far the premier blogging dest
73.
by jforman 10y ago
The Ubiquiti APs (e.g., the AC-PRO) can uplink to each other wirelessly, but only through one hop.
74.
by jforman 10y ago
This is probably sufficient for many angel investors, a few seed investors, and very few series A investors. No matter how much homework you've done on a company you can't responsibly deploy $5M after 20 minutes of diligence on t
75.
by jforman 10y ago
Funny, their Sequoia board member was bragging about going cash flow positive today.
76.
by jforman 10y ago
One epic failure and suddenly the entire discipline of investment banking, which moves mind-boggling amounts of money every day, is worthless?
77.
by jforman 10y ago
...unless later modified by a contract ENTERED INTO by the parties... Most types of contracts do not need to be signed.
78.
It’s Time to Get Rid of Non-Competes in Massachusetts(medium.com)
2 points by jforman 11y ago|0 comments
79.
by jforman 11y ago
A lab at Cleveland Clinic was placed in Immediate Jeopardy status a few months ago. They voluntarily stopped some services temporarily and were fined $600,000. http://www.beckershospitalreview.com/quality/cms-fines-cle
80.
by jforman 11y ago
CMS administers the CLIA program. This is about their ability to operate as a lab, not just about Medicare reimbursement. See here for a clear breakdown of responsibility among government agencies: http://www.fda.gov/Medica
81.
by jforman 11y ago
I worked at the Broad in a past life. I find it shocking that Cell let Lander publish his article without a conflict of interest statement, considering a) a key patent just went into interference proceedings and b) most people assume a Nob
82.
by jforman 11y ago
According to the Warning Letter, Pathway never registered with the FDA, never received clearance, and never performed any (reported) clinical trials. The key sentence from the letter is: "We have conducted a review of our files and ha
83.
Editas Medicine (gene editing with CRISPR) files for IPO two years after founding(sec.gov)
2 points by jforman 11y ago|0 comments
84.
by jforman 11y ago
CRISPR is far from being the first technology to be held up in the United States while being available elsewhere. There is very little chance the FDA will materially budge on their standards, and even less chance the FDA will be abolished.
85.
by jforman 11y ago
Depends on what license was communicated with the books when you downloaded them (or that is in the books themselves). If there's no license specified, default is "all rights reserved" and you cannot distribute the books to y
86.
by jforman 11y ago
The greatest barrier here is the FDA. They don't let you perform medical interventions (even breakthroughs like this) without going through a rigorous process. Companies like Editas ($43M Series A) are going through those motions rig
87.
by jforman 11y ago
Having been both a scientist and, now, a product manager for a medical device, I think science would benefit from the work around verification vs. validation: https://en.wikipedia.org/wiki/Verification_and_validation A
88.
by jforman 11y ago
I'm scared for the future of Congress. What thoughtful person would want to enter that environment?
89.
by jforman 11y ago
Probably more important than probiotics are patents for biologically engineered bacteria, like those made by Ginkgo Bioworks. A lot of work goes into engineering bugs to execute specific chemical synthesis pathways, and it's trivial t
90.
by jforman 11y ago
Baby steps to taking on Okta et al. They're going up market with this launch — doesn't seem wise to jump too far at once.

More ›